$ABUS
Arbutus Biopharma Corp

2017 Q1 Form 10-K Financial Statement

#000162828017002760 Filed on March 22, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2015 Q4 2015 Q3
Revenue $235.0K $12.69M $4.065M
YoY Change -61.03% 191.63% -6.81%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.330M $8.350M $7.710M
YoY Change -40.03% 171.1% 338.07%
% of Gross Profit
Research & Development $13.87M $14.90M $16.35M
YoY Change 5.54% 25.21% 75.66%
% of Gross Profit
Depreciation & Amortization $334.0K $170.0K $153.0K
YoY Change 53.92% 54.55% 9.29%
% of Gross Profit
Operating Expenses $18.53M $23.42M $62.20M
YoY Change -9.94% 55.1% 454.89%
Operating Profit -$18.30M -$11.76M -$58.14M
YoY Change -8.4% 9.41% 749.47%
Interest Expense $42.00K $6.280M $13.96M
YoY Change 24.6% -893.18%
% of Operating Profit
Other Income/Expense, Net -$328.0K $13.96M
YoY Change -107.99%
Pretax Income -$18.63M -$6.250M -$44.18M
YoY Change 17.39% 1.3% 413.7%
Income Tax -$990.0K -$15.20M
% Of Pretax Income
Net Earnings -$18.63M -$5.264M -$28.98M
YoY Change 17.34% -14.66% 236.84%
Net Earnings / Revenue -7926.38% -41.49% -712.96%
Basic Earnings Per Share
Diluted Earnings Per Share -$343.0K -$102.9K -$570.9K
COMMON SHARES
Basic Shares Outstanding 55.02M shares 54.33M
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1 2015 Q4 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $110.4M $181.3M $196.1M
YoY Change -36.04% 61.59% 80.24%
Cash & Equivalents $29.85M $166.8M $181.1M
Short-Term Investments $80.50M $14.50M $15.00M
Other Short-Term Assets $1.600M $1.200M $1.200M
YoY Change 6.67% -29.41% 71.43%
Inventory
Prepaid Expenses
Receivables $7.878M $1.008M $2.600M
Other Receivables $300.0K $300.0K $100.0K
Total Short-Term Assets $120.3M $183.9M $200.0M
YoY Change -31.18% 57.95% 79.05%
LONG-TERM ASSETS
Property, Plant & Equipment $11.46M $3.183M $2.300M
YoY Change 253.55% 80.85% 43.75%
Goodwill $24.36M $162.5M
YoY Change -85.01%
Intangibles $99.45M $352.6M
YoY Change -71.8%
Long-Term Investments $10.10M $10.00M
YoY Change -14.53%
Other Assets $12.60M
YoY Change
Total Long-Term Assets $147.9M $528.4M $522.6M
YoY Change -72.02% 29923.24% 3800.0%
TOTAL ASSETS
Total Short-Term Assets $120.3M $183.9M $200.0M
Total Long-Term Assets $147.9M $528.4M $522.6M
Total Assets $268.1M $712.3M $722.6M
YoY Change -61.87% 502.73% 477.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.600M $2.600M $2.900M
YoY Change -60.0% 30.0% -14.71%
Accrued Expenses $5.300M $5.900M $4.300M
YoY Change 55.88% -15.71% 79.17%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.87M $10.58M $13.80M
YoY Change -2.17% -47.65% -29.23%
LONG-TERM LIABILITIES
Long-Term Debt $12.00M $0.00 $0.00
YoY Change
Other Long-Term Liabilities $14.90M $7.700M $13.60M
YoY Change 93.51% -22.22% 34.65%
Total Long-Term Liabilities $26.90M $7.700M $13.60M
YoY Change 249.35% -22.22% 34.65%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.87M $10.58M $13.80M
Total Long-Term Liabilities $26.90M $7.700M $13.60M
Total Liabilities $79.04M $164.6M $168.8M
YoY Change -52.15% 446.1% 470.27%
SHAREHOLDERS EQUITY
Retained Earnings -$669.8M -$267.0M
YoY Change 136.79% 29.69%
Common Stock $870.8M $834.2M
YoY Change 3.61% 187.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $189.1M $547.7M $553.8M
YoY Change
Total Liabilities & Shareholders Equity $268.1M $712.3M $722.6M
YoY Change -61.87% 502.73% 477.62%

Cashflow Statement

Concept 2017 Q1 2015 Q4 2015 Q3
OPERATING ACTIVITIES
Net Income -$18.63M -$5.264M -$28.98M
YoY Change 17.34% -14.66% 236.84%
Depreciation, Depletion And Amortization $334.0K $170.0K $153.0K
YoY Change 53.92% 54.55% 9.29%
Cash From Operating Activities -$17.54M -$16.62M -$2.527M
YoY Change 51.87% 142.98% -62.45%
INVESTING ACTIVITIES
Capital Expenditures $3.423M -$1.180M $589.0K
YoY Change 1140.22% 257.58% -492.67%
Acquisitions
YoY Change
Other Investing Activities $26.62M -$630.0K -$17.14M
YoY Change -300.0% -145.65% 5810.34%
Cash From Investing Activities $23.20M -$1.810M -$17.73M
YoY Change -270.78% -270.75% 3840.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $354.0K -30.00K $116.0K
YoY Change 207.83% -106.38% -83.19%
NET CHANGE
Cash From Operating Activities -$17.54M -16.62M -$2.527M
Cash From Investing Activities $23.20M -1.810M -$17.73M
Cash From Financing Activities $354.0K -30.00K $116.0K
Net Change In Cash $6.014M -18.46M -$20.14M
YoY Change -124.04% 247.65% 210.39%
FREE CASH FLOW
Cash From Operating Activities -$17.54M -$16.62M -$2.527M
Capital Expenditures $3.423M -$1.180M $589.0K
Free Cash Flow -$20.96M -$15.44M -$3.116M
YoY Change 77.28% 137.17% -52.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 abus Accrued Payroll Current
AccruedPayrollCurrent
2331000 USD
CY2016Q4 abus Accrued Payroll Current
AccruedPayrollCurrent
2178000 USD
CY2015Q4 abus Accrued Researchand Development Current
AccruedResearchandDevelopmentCurrent
2358000 USD
CY2016Q4 abus Accrued Researchand Development Current
AccruedResearchandDevelopmentCurrent
3131000 USD
CY2016 abus Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards
AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards
3621000 USD
CY2016 abus Adjustmentsto Additional Paidin Capital Reclassificationof Equityto Liability Stock Option Awards
AdjustmentstoAdditionalPaidinCapitalReclassificationofEquitytoLiabilityStockOptionAwards
3243000 USD
CY2014 abus Balance Weightedaverageremainingcontractuallife
BalanceWeightedaverageremainingcontractuallife
P1Y9M18D
CY2015 abus Balance Weightedaverageremainingcontractuallife
BalanceWeightedaverageremainingcontractuallife
P9M18D
CY2016 abus Balance Weightedaverageremainingcontractuallife
BalanceWeightedaverageremainingcontractuallife
P2M12D
CY2015Q1 abus Business Acquisition Equity Interest Issued Or Issuable Value Assigned Attributed As Post Combination Service And Not Included As Part Of Total Purchase Price
BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice
56934000 USD
CY2015Q3 abus Business Combination Acceleration Of Share Based Compensation Expense Per Quarter
BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter
1900000 USD
CY2015 abus Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
18750 shares
CY2016 abus Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
170500 shares
CY2015 abus Class Of Warrant Or Right Exercised During Period Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
2.25
CY2015 abus Class Of Warrant Or Right Exercised During Period Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
2.88
CY2016 abus Class Of Warrant Or Right Exercised During Period Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
3.35
CY2016 abus Class Of Warrant Or Right Exercised During Period Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
2.53
CY2014Q4 abus Class Of Warrant Or Right Price Of Warrants Or Rights Intrinsic Value
ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue
5902000 CAD
CY2014Q4 abus Class Of Warrant Or Right Price Of Warrants Or Rights Intrinsic Value
ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue
5343000 USD
CY2015Q4 abus Class Of Warrant Or Right Price Of Warrants Or Rights Intrinsic Value
ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue
879000 USD
CY2015Q4 abus Class Of Warrant Or Right Price Of Warrants Or Rights Intrinsic Value
ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue
1217000 CAD
CY2016Q4 abus Class Of Warrant Or Right Price Of Warrants Or Rights Intrinsic Value
ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue
104000 USD
CY2016Q4 abus Class Of Warrant Or Right Price Of Warrants Or Rights Intrinsic Value
ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue
139000 CAD
CY2016Q2 abus Classof Warrantor Right Expired
ClassofWarrantorRightExpired
8000 shares
CY2016 abus Classof Warrantor Right Expired
ClassofWarrantorRightExpired
8000 shares
CY2016Q4 abus Common Shares Attributedto Post Acquisition Period Compensation Cost Not Yet Recognized Over Expiry Periodof Repurchase Provision Rights
CommonSharesAttributedtoPostAcquisitionPeriodCompensationCostNotYetRecognizedOverExpiryPeriodofRepurchaseProvisionRights
7972000 USD
CY2016 abus Cumulative Contributionfor Product
CumulativeContributionforProduct
2756000 USD
CY2016 abus Cumulative Contributionfor Product
CumulativeContributionforProduct
3702000 CAD
CY2015Q4 abus Deferred Tax Asset Book Amortization In Excess Of Tax
DeferredTaxAssetBookAmortizationInExcessOfTax
2142000 USD
CY2016Q4 abus Deferred Tax Asset Book Amortization In Excess Of Tax
DeferredTaxAssetBookAmortizationInExcessOfTax
451000 USD
CY2015Q4 abus Deferred Tax Asset Revenue Recognized For Tax Purposes In Excess Of Revenue Recognized For Accounting Purposes
DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes
281000 USD
CY2016Q4 abus Deferred Tax Asset Revenue Recognized For Tax Purposes In Excess Of Revenue Recognized For Accounting Purposes
DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes
410000 USD
CY2015Q4 abus Deferred Tax Asset Tax Value In Excess Of Accounting Value In Lease Inducements
DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements
77000 USD
CY2016Q4 abus Deferred Tax Asset Tax Value In Excess Of Accounting Value In Lease Inducements
DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements
58000 USD
CY2015Q4 abus Deferred Tax Asset Upfront License Fees
DeferredTaxAssetUpfrontLicenseFees
629000 USD
CY2016Q4 abus Deferred Tax Asset Upfront License Fees
DeferredTaxAssetUpfrontLicenseFees
536000 USD
CY2015Q4 abus Employee Stock Options Liability Classified Outstanding
EmployeeStockOptionsLiabilityClassifiedOutstanding
0 USD
CY2016Q4 abus Employee Stock Options Liability Classified Outstanding
EmployeeStockOptionsLiabilityClassifiedOutstanding
553000 USD
CY2016Q4 abus Employee Stock Options Liability Classified Outstanding Fair Value Disclosure
EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure
553000 USD
CY2014 abus Fair Value Of Warrants Exercised In The Period
FairValueOfWarrantsExercisedInThePeriod
10208000 USD
CY2015 abus Fair Value Of Warrants Exercised In The Period
FairValueOfWarrantsExercisedInThePeriod
334000 USD
CY2016 abus Fair Value Of Warrants Exercised In The Period
FairValueOfWarrantsExercisedInThePeriod
247000 USD
CY2015Q4 abus Fair Value Of Warrants Outstanding Per Warrant
FairValueOfWarrantsOutstandingPerWarrant
2.33
CY2016Q4 abus Fair Value Of Warrants Outstanding Per Warrant
FairValueOfWarrantsOutstandingPerWarrant
0.53
CY2014 abus Fair Value Warrants Foreign Exchange Gain Loss
FairValueWarrantsForeignExchangeGainLoss
-455000 USD
CY2015 abus Fair Value Warrants Foreign Exchange Gain Loss
FairValueWarrantsForeignExchangeGainLoss
-541000 USD
CY2016 abus Fair Value Warrants Foreign Exchange Gain Loss
FairValueWarrantsForeignExchangeGainLoss
0 USD
CY2014 abus Increase Decrease In Value Of Warrants
IncreaseDecreaseInValueOfWarrants
10383000 USD
CY2015 abus Increase Decrease In Value Of Warrants
IncreaseDecreaseInValueOfWarrants
-3341000 USD
CY2016 abus Increase Decrease In Value Of Warrants
IncreaseDecreaseInValueOfWarrants
-529000 USD
CY2014 abus Increase Decrease Other Deferred Costs Net
IncreaseDecreaseOtherDeferredCostsNet
-167000 USD
CY2015 abus Increase Decrease Other Deferred Costs Net
IncreaseDecreaseOtherDeferredCostsNet
0 USD
CY2014 abus Fair Valueof Warrants Exercisedona Cashless Basis
FairValueofWarrantsExercisedonaCashlessBasis
-116000 USD
CY2015 abus Fair Valueof Warrants Exercisedona Cashless Basis
FairValueofWarrantsExercisedonaCashlessBasis
0 USD
CY2016 abus Fair Valueof Warrants Exercisedona Cashless Basis
FairValueofWarrantsExercisedonaCashlessBasis
0 USD
CY2014 abus Increase Decrease In Fair Value Of Contingent Consideration Liability
IncreaseDecreaseInFairValueOfContingentConsiderationLiability
0 USD
CY2015 abus Increase Decrease In Fair Value Of Contingent Consideration Liability
IncreaseDecreaseInFairValueOfContingentConsiderationLiability
770000 USD
CY2016 abus Increase Decrease In Fair Value Of Contingent Consideration Liability
IncreaseDecreaseInFairValueOfContingentConsiderationLiability
1568000 USD
CY2016 abus Increase Decrease Other Deferred Costs Net
IncreaseDecreaseOtherDeferredCostsNet
0 USD
abus Maximum Contribution For Product
MaximumContributionForProduct
9330000 CAD
abus Maximum Contribution For Product
MaximumContributionForProduct
7179000 USD
CY2015Q4 abus Net Liquidity
NetLiquidity
172477000 USD
CY2016Q4 abus Net Liquidity
NetLiquidity
120649000 USD
CY2014Q1 abus Number Of Additional Shares Authorized
NumberOfAdditionalSharesAuthorized
318750 shares
CY2006Q2 abus Number Of Chemotherapy Products With Worldwide Licenses
NumberOfChemotherapyProductsWithWorldwideLicenses
3 chemotherapy_products
CY2013Q4 abus Number Of Executive Officers Granted Options With New Appointments
NumberOfExecutiveOfficersGrantedOptionsWithNewAppointments
2 executive_officers
CY2016Q4 abus Numberof Share Based Compensation Plans
NumberofShareBasedCompensationPlans
7 compensation_plan
CY2016Q2 abus Numberof Shareholders Subjectto Repurchase Provision
NumberofShareholdersSubjecttoRepurchaseProvision
4 shareholder
CY2016Q2 abus Numberof Shareholders Whose Departure Accelerated Compensation Expense
NumberofShareholdersWhoseDepartureAcceleratedCompensationExpense
2 shareholder
CY2014 abus Option Exercised Contractual Option Revenue Amount
OptionExercisedContractualOptionRevenueAmount
0 USD
CY2015 abus Option Exercised Contractual Option Revenue Amount
OptionExercisedContractualOptionRevenueAmount
0 USD
CY2016 abus Option Exercised Contractual Option Revenue Amount
OptionExercisedContractualOptionRevenueAmount
1000000 USD
CY2011Q4 abus Patent Tax Refund Percentage
PatentTaxRefundPercentage
0.75
abus Percent Of Costs Funded By Tpc
PercentOfCostsFundedByTPC
0.27
CY2014Q1 abus Potential Proceeds Of Additional Shares Authorized
PotentialProceedsOfAdditionalSharesAuthorized
9084000 USD
CY2015Q1 abus Potential Proceeds Of Additional Shares Authorized
PotentialProceedsOfAdditionalSharesAuthorized
22781000 USD
CY2014Q1 abus Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
56477000 USD
CY2015Q1 abus Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
142177000 USD
CY2016 abus Restricted Investment Term
RestrictedInvestmentTerm
P2Y
CY2016 abus Royalty Guarantees Commitments Percentage
RoyaltyGuaranteesCommitmentsPercentage
0.025
CY2015Q4 abus Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Nonvested Weighted Average Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue
11.34
CY2015Q4 abus Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Nonvested Weighted Average Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue
15.69
CY2016Q4 abus Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Nonvested Weighted Average Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue
5.34
CY2016Q4 abus Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Nonvested Weighted Average Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue
7.17
CY2016 abus Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Reclassificationto Liability Nonvested Weighted Average Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsReclassificationtoLiabilityNonvestedWeightedAverageFairValue
7.80
CY2016 abus Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Reclassificationto Liability Nonvested Weighted Average Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsReclassificationtoLiabilityNonvestedWeightedAverageFairValue
10.80
CY2016 abus Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Vested In Period Weighted Average Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue
10.72
CY2016 abus Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Vested In Period Weighted Average Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue
14.20
CY2016 abus Sharebased Compensation Arrangementby Sharebased Payment Award Options Nonvested Reclassificationto Liability Numberof Shares
SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedReclassificationtoLiabilityNumberofShares
134000 shares
CY2016 abus Sharebased Compensation Arrangementby Sharebased Payment Award Options Reclassificationsto Liabilityin Period Intrinsic Value
SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsReclassificationstoLiabilityinPeriodIntrinsicValue
604000 USD
CY2016 abus Sharebased Compensation Arrangementby Sharebased Payment Award Options Reclassificationsto Liabilityin Period Intrinsic Value
SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsReclassificationstoLiabilityinPeriodIntrinsicValue
836000 CAD
CY2016 abus Sharebased Compensation Arrangementsby Sharebased Payment Award Options Reclassificationsto Liabilityin Period Weighted Average Exercise Price
SharebasedCompensationArrangementsbySharebasedPaymentAwardOptionsReclassificationstoLiabilityinPeriodWeightedAverageExercisePrice
7.24
CY2016 abus Sharebased Compensation Arrangementsby Sharebased Payment Award Options Reclassificationsto Liabilityin Period Weighted Average Exercise Price
SharebasedCompensationArrangementsbySharebasedPaymentAwardOptionsReclassificationstoLiabilityinPeriodWeightedAverageExercisePrice
5.23
CY2016 abus Threshold Period To Pay Accounts Payables
ThresholdPeriodToPayAccountsPayables
P45D
CY2015 abus Warrants Exercised
WarrantsExercised
18750 shares
CY2016 abus Warrants Exercised
WarrantsExercised
170500 shares
CY2016Q4 abus Wholly Owned Subsidiaries Includedin Financial Statements
WhollyOwnedSubsidiariesIncludedinFinancialStatements
2 subsidiary
CY2016 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2016 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2016 dei Amendment Flag
AmendmentFlag
false
CY2016 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2016 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016 dei Document Period End Date
DocumentPeriodEndDate
2016-12-31
CY2016 dei Document Type
DocumentType
10-K
CY2016 dei Entity Central Index Key
EntityCentralIndexKey
0001447028
CY2017Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
55023207 shares
CY2016Q2 dei Entity Public Float
EntityPublicFloat
190692659 USD
CY2016 dei Entity Registrant Name
EntityRegistrantName
Arbutus Biopharma Corp
CY2016 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016 invest Investment Interest Rate
InvestmentInterestRate
0.0125
CY2015Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
8827000 USD
CY2016Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
9910000 USD
CY2015Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
8827000 USD
CY2016Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
9910000 USD
CY2015Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
2610000 USD
CY2016Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
3215000 USD
CY2015Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
1008000 USD
CY2016Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
273000 USD
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1008000 USD
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
273000 USD
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
640000 USD
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
498000 USD
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9729000 USD
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10738000 USD
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-49782000 USD
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-49782000 USD
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
30206000 USD
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
36543000 USD
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3283000 USD
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22093000 USD
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
38162000 USD
CY2014 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
2462000 USD
CY2015 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
4085000 USD
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3283000 USD
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22093000 USD
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
39159000 USD
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2221233 shares
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2899331 shares
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4645864 shares
CY2016 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2015 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
770000 USD
CY2016 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
1568000 USD
CY2015Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
7497000 USD
CY2016 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68717000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72187000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
166779000 USD
CY2015Q4 us-gaap Assets
Assets
712291000 USD
CY2016Q4 us-gaap Assets
Assets
275919000 USD
CY2015Q4 us-gaap Assets Current
AssetsCurrent
183882000 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
132564000 USD
CY2015Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
191374000 USD
CY2016Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
143160000 USD
CY2014 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
462000 USD
CY2015 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
9656000 USD
CY2016 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
0 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
770000 USD
CY2014 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 USD
CY2016Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
9065000 USD
CY2015Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
6727000 USD
CY2014 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
CY2015 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1057000 USD
CY2014 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0 USD
CY2015 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
324000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23413000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
166779000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
23413000 USD
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3470000 USD
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
94592000 USD
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-143366000 USD
CY2015Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
181304000 USD
CY2016Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
130559000 USD
CY2014Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.67
CY2014Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.95
CY2015Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.95
CY2015Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.13
CY2016Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.60
CY2016Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.94
CY2014Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
398250 shares
CY2015Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
379500 shares
CY2016Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
201000 shares
CY2015Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
379500 shares
CY2016Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
201000 shares
CY2015Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2016Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54570691 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54841494 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54570691 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54841494 shares
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
834240000 USD
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
867393000 USD
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-45326000 USD
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-88590000 USD
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-384164000 USD
CY2014 us-gaap Contracts Revenue
ContractsRevenue
11738000 USD
CY2015 us-gaap Contracts Revenue
ContractsRevenue
13309000 USD
CY2016 us-gaap Contracts Revenue
ContractsRevenue
229000 USD
CY2014 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2015 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-16185000 USD
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-105061000 USD
CY2015Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
104830000 USD
CY2015Q4 us-gaap Deferred Revenue
DeferredRevenue
1081000 USD
CY2016Q4 us-gaap Deferred Revenue
DeferredRevenue
15000 USD
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
868000 USD
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
15000 USD
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
213000 USD
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0 USD
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
17274000 USD
CY2015Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
13474000 USD
CY2016Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
16986000 USD
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
13932000 USD
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
24275000 USD
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
14621000 USD
CY2015Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
0 USD
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1435000 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1454000 USD
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
777000 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
486000 USD
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
41494000 USD
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
58537000 USD
CY2015Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
146324000 USD
CY2016Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
41263000 USD
CY2015Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
146324000 USD
CY2016Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
41263000 USD
CY2015Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
146324000 USD
CY2016Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
41263000 USD
CY2014 us-gaap Depreciation
Depreciation
529000 USD
CY2015 us-gaap Depreciation
Depreciation
589000 USD
CY2016 us-gaap Depreciation
Depreciation
1092000 USD
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.80
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.34
CY2016 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.24
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.57
CY2015Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.34
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.47
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.05
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.24
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.80
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.34
CY2016 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.24
CY2014 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-1827000 USD
CY2015 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-2175000 USD
CY2016 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
1004000 USD
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.26
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.26
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.26
CY2016Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
8835000 USD
CY2016 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P12M
CY2015 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0
CY2016 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0
CY2015 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P7M6D
CY2016 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P2M12D
CY2015 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.4907
CY2016 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.4195
CY2015 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0048
CY2016 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0076
CY2014 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-10383000 USD
CY2015 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
3341000 USD
CY2016 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
530000 USD
CY2014 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
4127000 USD
CY2015 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
21771000 USD
CY2016 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1120000 USD
CY2014 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
4218000 USD
CY2015 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
21966000 USD
CY2016 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
1003000 USD
CY2014 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
80000 USD
CY2015 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
CY2016 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-174000 USD
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8683000 USD
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26438000 USD
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
39438000 USD
CY2015Q4 us-gaap Goodwill
Goodwill
162514000 USD
CY2016Q4 us-gaap Goodwill
Goodwill
24364000 USD
CY2016 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
391347000 USD
CY2014 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2015 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2016 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
138150000 USD
CY2014 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 USD
CY2015 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
39007000 USD
CY2016 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
253197000 USD
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-38837000 USD
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-77306000 USD
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-489166000 USD
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-16185000 USD
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-105002000 USD
CY2014 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
6599000 USD
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3675000 USD
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
17043000 USD
CY2014 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
0 USD
CY2015 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-7874000 USD
CY2016 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-47962000 USD
CY2014 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-10097000 USD
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-20100000 USD
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-127183000 USD
CY2014 us-gaap Income Tax Reconciliation Nondeductible Expense Impairment Losses
IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
0 USD
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Impairment Losses
IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
0 USD
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Impairment Losses
IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
46971000 USD
CY2014 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
904000 USD
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
7345000 USD
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
9727000 USD
CY2014 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
2594000 USD
CY2015 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
769000 USD
CY2016 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-3598000 USD
CY2015Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
246000 USD
CY2016Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
293000 USD
CY2014 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
6253000 USD
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2489000 USD
CY2016 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
26000 USD
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1887000 USD
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-628000 USD
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-735000 USD
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
13171000 USD
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-13090000 USD
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1066000 USD
CY2014 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
52000 USD
CY2015 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
188000 USD
CY2016 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
47000 USD
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
773000 USD
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-159000 USD
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
115000 USD
CY2014 us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
360000 USD
CY2015 us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-349000 USD
CY2016 us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
USD
CY2015Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
352642000 USD
CY2016Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
99445000 USD
CY2014 us-gaap Investment Income Interest
InvestmentIncomeInterest
853000 USD
CY2015 us-gaap Investment Income Interest
InvestmentIncomeInterest
674000 USD
CY2016 us-gaap Investment Income Interest
InvestmentIncomeInterest
1391000 USD
CY2015 us-gaap Investment Tax Credit
InvestmentTaxCredit
196000 USD
CY2016 us-gaap Investment Tax Credit
InvestmentTaxCredit
145000 USD
CY2015Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
14525000 USD
CY2016Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
107146000 USD
CY2015Q4 us-gaap Lease Incentive Payable Current
LeaseIncentivePayableCurrent
297000 USD
CY2016Q4 us-gaap Lease Incentive Payable Current
LeaseIncentivePayableCurrent
350000 USD
CY2015Q4 us-gaap Liabilities
Liabilities
164612000 USD
CY2016Q4 us-gaap Liabilities
Liabilities
72914000 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
712291000 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
275919000 USD
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10578000 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10585000 USD
CY2015Q4 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
8380000 USD
CY2016Q4 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
9725000 USD
CY2014 us-gaap Licenses Revenue
LicensesRevenue
3215000 USD
CY2015 us-gaap Licenses Revenue
LicensesRevenue
11564000 USD
CY2016 us-gaap Licenses Revenue
LicensesRevenue
1262000 USD
CY2015Q4 us-gaap Long Term Investments
LongTermInvestments
10070000 USD
CY2016Q4 us-gaap Long Term Investments
LongTermInvestments
0 USD
CY2015Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
0 USD
CY2016Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
12001000 USD
CY2014 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
60676000 USD
CY2015 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
143870000 USD
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12638000 USD
CY2014 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-42958000 USD
CY2015 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
7682000 USD
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-99123000 USD
CY2014 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12421000 USD
CY2015 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-54785000 USD
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-57885000 USD
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-38837000 USD
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-11989000 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-14886000 USD
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-28982000 USD
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-5264000 USD
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-61121000 USD
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-15874000 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-130000000 USD
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-19595000 USD
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-218695000 USD
CY2015Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
20.25
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
5000000 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
6790414 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
800000 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
10000 USD
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 USD
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.50
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
10.07
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
2.53
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
3.35
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
9.70
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.33
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P30D
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P30D
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
56000 USD
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
1351541 shares
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2211963 shares
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-384164000 USD
CY2014 us-gaap Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
0 USD
CY2015 us-gaap Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
381618000 USD
CY2016 us-gaap Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
0 USD
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5403000 USD
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
25016000 USD
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2473000 USD
CY2016 us-gaap Number Of Reporting Units
NumberOfReportingUnits
1 reporting_unit
CY2014 us-gaap Operating Expenses
OperatingExpenses
48387000 USD
CY2015 us-gaap Operating Expenses
OperatingExpenses
127195000 USD
CY2016 us-gaap Operating Expenses
OperatingExpenses
493130000 USD
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-33434000 USD
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-18006000 USD
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14420000 USD
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-58138000 USD
CY2015Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-11758000 USD
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-102322000 USD
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-19977000 USD
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-195248000 USD
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-18975000 USD
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-257439000 USD
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-491639000 USD
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
9361293 USD
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1475444 USD
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
656469 USD
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1203863 USD
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1539323 USD
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
4486194 USD
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1133000 USD
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1158000 USD
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1341000 USD
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
591000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
538000 USD
CY2014 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-6489000 USD
CY2015 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-27469000 USD
CY2016 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 USD
CY2014 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
41982000 USD
CY2015 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-9645000 USD
CY2016 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
82551000 USD
CY2014Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
4085000 USD
CY2015Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
9700000 USD
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1056000 USD
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2287000 USD
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3996000 USD
CY2014 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
0 USD
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
322698 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
3500000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1088908 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
938730 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
699241 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1125000 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1789599 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.89
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
192000 USD
CY2014 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1583000 USD
CY2015 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
42000 USD
CY2016 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
445000 USD
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
142177000 USD
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12912000 USD
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
17683000 USD
CY2014 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
CY2015 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
CY2016 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
12001000 USD
CY2014 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
80000 USD
CY2015 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
CY2016 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
25000 USD
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2616000 USD
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1651000 USD
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2505000 USD
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1718000 USD
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
5058000 USD
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
472479 shares
CY2015 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
0 USD
CY2016 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
12601000 USD
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1196000 USD
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1311000 USD
CY2014 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
0 USD
CY2015 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
24000 USD
CY2016 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
0 USD
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
60562000 USD
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
151875000 USD
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
56477000 USD
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3183000 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6945000 USD
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38713000 USD
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
51505000 USD
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
61253000 USD
CY2016Q4 us-gaap Restricted Investments At Fair Value
RestrictedInvestmentsAtFairValue
12601000 USD
CY2015Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
0 USD
CY2016Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
12601000 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-266985000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-651149000 USD
CY2015 us-gaap Revenue From Grants
RevenueFromGrants
1245000 USD
CY2016 us-gaap Revenue From Grants
RevenueFromGrants
129000 USD
CY2014 us-gaap Revenues
Revenues
14953000 USD
CY2015Q1 us-gaap Revenues
Revenues
4682000 USD
CY2015Q2 us-gaap Revenues
Revenues
3440000 USD
CY2015Q3 us-gaap Revenues
Revenues
4065000 USD
CY2015Q4 us-gaap Revenues
Revenues
12686000 USD
CY2015 us-gaap Revenues
Revenues
24873000 USD
CY2016Q1 us-gaap Revenues
Revenues
603000 USD
CY2016 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P7Y5M27D
CY2015Q4 us-gaap Short Term Investments
ShortTermInvestments
14525000 USD
CY2016Q4 us-gaap Short Term Investments
ShortTermInvestments
107146000 USD
CY2015 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
0 shares
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2125000 shares
CY2015Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7500000 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.15
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3765094 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
2626000 USD
CY2016Q2 us-gaap Revenues
Revenues
309000 USD
CY2016Q3 us-gaap Revenues
Revenues
774000 USD
CY2016Q4 us-gaap Revenues
Revenues
-195000 USD
CY2016 us-gaap Revenues
Revenues
1491000 USD
CY2014Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
28.50
CY2015 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
381942000 USD
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
56477000 USD
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
142177000 USD
CY2014 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
11791000 USD
CY2015 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
371000 USD
CY2016 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
692000 USD
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2616000 USD
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1651000 USD
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
258000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
59194000 USD
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
88035000 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
547679000 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
203005000 USD
CY2015Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
128000 USD
CY2016Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
128000 USD
CY2015Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
883000 USD
CY2016Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
107000 USD
CY2013Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
5379000 USD
CY2014Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
5099000 USD
CY2015Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
883000 USD
CY2016Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
107000 USD
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21603136 shares
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45462324 shares
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53074401 shares
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21603136 shares
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45462324 shares
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53074401 shares
CY2016 us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of business and future operations</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus Biopharma Corporation (the &#8220;Company&#8221; or &#8220;Arbutus&#8221;) is a biopharmaceutical business dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by the hepatitis B virus (&#8220;HBV&#8221;). The Company is also developing a pipeline focused on advancing novel RNA interference therapeutics ("RNAi") leveraging the Company&#8217;s expertise in Lipid Nanoparticle ("LNP") technology.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The continuation of the research and development activities and the commercialization of its products are dependent on the Company&#8217;s ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of future research and development programs or the Company&#8217;s ability to continue to fund these programs in the future.</font></div></div>
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of estimates</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, revenue, expenses, contingent assets and contingent liabilities as at the end or during the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring the use of management estimates relate valuation of intangible assets and goodwill, recognition of revenue, stock-based compensation, and financial instruments, and the amounts recorded as accrued liabilities, contingent consideration, and income tax recovery.</font></div></div>

Files In Submission

Name View Source Status
0001628280-17-002760-index-headers.html Edgar Link pending
0001628280-17-002760-index.html Edgar Link pending
0001628280-17-002760.txt Edgar Link pending
0001628280-17-002760-xbrl.zip Edgar Link pending
abus-20161231.xml Edgar Link completed
abus-20161231.xsd Edgar Link pending
abus-20161231_cal.xml Edgar Link unprocessable
abus-20161231_def.xml Edgar Link unprocessable
abus-20161231_lab.xml Edgar Link unprocessable
abus-20161231_pre.xml Edgar Link unprocessable
arb1467clinicaldesign.jpg Edgar Link pending
arb1467triggers.jpg Edgar Link pending
arb1740clinicaldesign.jpg Edgar Link pending
arbutus10k2016.htm Edgar Link pending
arbutus10k2_chart-04659.jpg Edgar Link pending
departmentofdefense.jpg Edgar Link pending
exhibit1062_dodtermination.htm Edgar Link pending
exhibit1063_neurovivetermi.htm Edgar Link pending
exhibit1064_dicernatermina.htm Edgar Link pending
exhibit1065_cytosterminati.htm Edgar Link pending
exhibit1066_billsymonds.htm Edgar Link pending
exhibit1067alexionagreemen.htm Edgar Link pending
exhibit211_listingofsubsid.htm Edgar Link pending
exhibit231_kpmgconsent.htm Edgar Link pending
exhibit311_10-kcertceo.htm Edgar Link pending
exhibit312_10-kcertcfo.htm Edgar Link pending
exhibit321_soxcertceo.htm Edgar Link pending
exhibit322_soxcertcfo.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hbvlifecycle.jpg Edgar Link pending
hbvpipeline.jpg Edgar Link pending
lnptechnology.jpg Edgar Link pending
markjmurraysig.jpg Edgar Link pending
phase2interimresults.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sandraoconnellsig.jpg Edgar Link pending
Show.js Edgar Link pending